Insights into the interaction of LVV-hemorphin-7 with Angiotensin II type 1 receptor

Amanat Ali, Elizabeth K.M. Johnstone, Bincy Baby, Heng B. See, Angela Song, K. Johan Rosengren, Kevin D.G. Pfleger, Mohammed Akli Ayoub, Ranjit Vijayan

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Hemorphins are known for their role in the control of blood pressure. Recently, we revealed the positive modulation of the angiotensin II (AngII) type 1 receptor (AT1R) by LVV-hemorphin-7 (LVV-H7) in human embryonic kidney (HEK293) cells. Here, we examined the molecular binding behavior of LVV-H7 on AT1R and its effect on AngII binding using a nanoluciferase-based biolu-minescence resonance energy transfer (NanoBRET) assay in HEK293FT cells, as well as molecular docking and molecular dynamics (MD) studies. Saturation and real-time kinetics supported the positive effect of LVV-H7 on the binding of AngII. While the competitive antagonist olmesartan competed with AngII binding, LVV-H7 slightly, but significantly, decreased AngII’s kD by 2.6 fold with no effect on its Bmax. Molecular docking and MD simulations indicated that the binding of LVV-H7 in the intracellular region of AT1R allosterically potentiates AngII binding. LVV-H7 targets residues on intracellular loops 2 and 3 of AT1R, which are known binding sites of allosteric modulators in other GPCRs. Our data demonstrate the allosteric effect of LVV-H7 on AngII binding, which is consistent with the positive modulation of AT1R activity and signaling previously reported. This further supports the pharmacological targeting of AT1R by hemorphins, with implications in vascular and renal physiology.

Original languageBritish English
Article number209
Pages (from-to)1-14
Number of pages14
JournalInternational Journal of Molecular Sciences
Issue number1
StatePublished - 1 Jan 2021


  • AngII
  • AT1R
  • Molecular docking
  • Molecular dynam-ics
  • NanoBRET
  • PAM
  • S LVV-hemorphin-7


Dive into the research topics of 'Insights into the interaction of LVV-hemorphin-7 with Angiotensin II type 1 receptor'. Together they form a unique fingerprint.

Cite this